Binayak Sinha1, Samit Ghosal2. 1. AMRI Hospitals, Kolkata, India. Electronic address: binayak.sinha@gmail.com. 2. Nightingale Hospital, Kolkata, India.
Abstract
AIM: To assess the effects DPP-4i; SGLT2-i & GLP1-RA on CV death, MI, stroke and hHF. This is probably the first meta-analysis to assess the effects of these drugs on MI and stroke in totality, including non-fatal & fatal MI and stroke. METHODS: Scientific databases were searched for RCTs with pre-specified inclusion criteria and each end-point from the selected 13 studies was reported as an effect size (M H odds ratio) with a 95% confidence interval P value. RESULTS: The pooled analysis of all the 5 available CVOT with DPP-4i resulted in a neutral effect on MI, stroke, the combined end points of MI & Stroke, CV death and hHF. The pooled analysis of all the 5 available CVOTs with GLP1-RA resulted in a neutral effect on MI. However, there was a statistically significant 12% reduction in CV death (P = 0.01), 13% reduction in stroke (P = 0.02) and 11% reduction the combined end points of MI & Stroke (P = 0.001). The impact of GLP1-RA inhibitors on hHF was neutral. The pooled analysis of all the 3 available CVOTs with SGLT2-i resulted in a neutral effect on MI, stroke, the combined end points of MI & Stroke and CV death. There was however a statistically significant 28% reduction in hHF (P < 0.001). CONCLUSION: DPP-4i & SGLT-2i are neutral as far as all aspects of CV outcomes are concerned except for hHF which is significantly reduced by the latter. GLP1-RA as a class reduce risk of ASCVD showing a significant reduction in MI and stroke.
AIM: To assess the effects DPP-4i; SGLT2-i & GLP1-RA on CV death, MI, stroke and hHF. This is probably the first meta-analysis to assess the effects of these drugs on MI and stroke in totality, including non-fatal & fatal MI and stroke. METHODS: Scientific databases were searched for RCTs with pre-specified inclusion criteria and each end-point from the selected 13 studies was reported as an effect size (M H odds ratio) with a 95% confidence interval P value. RESULTS: The pooled analysis of all the 5 available CVOT with DPP-4i resulted in a neutral effect on MI, stroke, the combined end points of MI & Stroke, CV death and hHF. The pooled analysis of all the 5 available CVOTs with GLP1-RA resulted in a neutral effect on MI. However, there was a statistically significant 12% reduction in CV death (P = 0.01), 13% reduction in stroke (P = 0.02) and 11% reduction the combined end points of MI & Stroke (P = 0.001). The impact of GLP1-RA inhibitors on hHF was neutral. The pooled analysis of all the 3 available CVOTs with SGLT2-i resulted in a neutral effect on MI, stroke, the combined end points of MI & Stroke and CV death. There was however a statistically significant 28% reduction in hHF (P < 0.001). CONCLUSION:DPP-4i & SGLT-2i are neutral as far as all aspects of CV outcomes are concerned except for hHF which is significantly reduced by the latter. GLP1-RA as a class reduce risk of ASCVD showing a significant reduction in MI and stroke.
Authors: Jason T Alexander; Erin M Staab; Wen Wan; Melissa Franco; Alexandra Knitter; M Reza Skandari; Shari Bolen; Nisa M Maruthur; Elbert S Huang; Louis H Philipson; Aaron N Winn; Celeste C Thomas; Meltem Zeytinoglu; Valerie G Press; Elizabeth L Tung; Kathryn Gunter; Brittany Bindon; Sanjay Jumani; Neda Laiteerapong Journal: J Gen Intern Med Date: 2021-11-30 Impact factor: 6.473
Authors: Husam Abdel-Qadir; Madison Gunn; Iliana C Lega; Andrea Pang; Peter C Austin; Sheldon M Singh; Cynthia A Jackevicius; Karen Tu; Paul Dorian; Douglas S Lee; Dennis T Ko Journal: J Am Heart Assoc Date: 2022-02-08 Impact factor: 6.106
Authors: Shu Ning Lin; Kok Kit Phang; Seng Hsiung Toh; Kok Han Chee; Hasniza Zaman Huri Journal: Front Endocrinol (Lausanne) Date: 2020-07-10 Impact factor: 5.555